Kündig T - Search Results

1

Component-resolved in vitro diagnosis in carrot allergy: does the use of recombinant carrot allergens improve the reliability of the diagnostic procedure?

Ballmer-Weber BK, Wangorsch A, Bohle B, Kaul S, Kündig T, Fötisch K, van Ree R, Vieths S. Ballmer-Weber BK, et al. Among authors: kundig t. Clin Exp Allergy. 2005 Jul;35(7):970-8. doi: 10.1111/j.1365-2222.2005.02294.x. Clin Exp Allergy. 2005. PMID: 16008686

2

Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens.

Johansen P, Senti G, Martínez Gómez JM, Wüthrich B, Bot A, Kündig TM. Johansen P, et al. Eur J Immunol. 2005 Dec;35(12):3591-8. doi: 10.1002/eji.200535076. Eur J Immunol. 2005. PMID: 16285011 Free article.

3

Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy.

Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wüthrich B, Bot A, Kündig TM. Johansen P, et al. Among authors: kundig tm. Clin Exp Allergy. 2005 Dec;35(12):1591-8. doi: 10.1111/j.1365-2222.2005.02384.x. Clin Exp Allergy. 2005. PMID: 16393325

4

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.

Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF. Kündig TM, et al. J Allergy Clin Immunol. 2006 Jun;117(6):1470-6. doi: 10.1016/j.jaci.2006.01.040. Epub 2006 Apr 27. J Allergy Clin Immunol. 2006. PMID: 16751015 Clinical Trial.

5

A cutaneous allergen neutralisation test that correlates with the duration of venom immunotherapy.

Senti G, Johansen P, Oliver R, Prinz Vavricka BM, Graf N, Wuthrich B, Kundig TM. Senti G, et al. Int Arch Allergy Immunol. 2006;141(4):377-83. doi: 10.1159/000095464. Epub 2006 Aug 30. Int Arch Allergy Immunol. 2006. PMID: 16943676

6

Medication with antihistamines impairs allergen-specific immunotherapy in mice.

Johansen P, Senti G, Maria Martínez Gómez J, Kündig TM. Johansen P, et al. Among authors: kundig tm. Clin Exp Allergy. 2008 Mar;38(3):512-9. doi: 10.1111/j.1365-2222.2007.02904.x. Epub 2007 Dec 13. Clin Exp Allergy. 2008. PMID: 18081882

7

Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy.

Martínez-Gómez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, Crameri R, Kündig TM. Martínez-Gómez JM, et al. Among authors: kundig tm. Allergy. 2009 Jan;64(1):172-8. doi: 10.1111/j.1398-9995.2008.01812.x. Epub 2008 Nov 28. Allergy. 2009. PMID: 19076537

8

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, Pfister T, Maurer P, Bachmann MF, Graf N, Kündig TM. Senti G, et al. Among authors: kundig tm. Clin Exp Allergy. 2009 Apr;39(4):562-70. doi: 10.1111/j.1365-2222.2008.03191.x. Epub 2009 Feb 16. Clin Exp Allergy. 2009. PMID: 19226280 Clinical Trial.

9

Intralymphatic injections as a new administration route for allergen-specific immunotherapy.

Martínez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kündig TM. Martínez-Gómez JM, et al. Int Arch Allergy Immunol. 2009;150(1):59-65. doi: 10.1159/000210381. Epub 2009 Apr 2. Int Arch Allergy Immunol. 2009. PMID: 19339803 Free article.

10

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.

Senti G, Graf N, Haug S, Rüedi N, von Moos S, Sonderegger T, Johansen P, Kündig TM. Senti G, et al. Among authors: kundig tm. J Allergy Clin Immunol. 2009 Nov;124(5):997-1002. doi: 10.1016/j.jaci.2009.07.019. Epub 2009 Sep 5. J Allergy Clin Immunol. 2009. PMID: 19733905 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

250 results

Search Page

Filters